Endometrial and Cervical Cancer Treatments

SEP 10, 2026 · REVIEW

Role of hypoxia-inducible factor – 1 alpha on the progression of cervical intraepithelial neoplasia and cervical cancer: a narrative review

Frontiers in Oncology

A narrative review synthesizing mechanistic evidence and experimental findings on HIF-1α in cervical cancer progression, raising questions about therapeutic targets rather than reporting clinical trial outcomes or definitive clinical evidence.

SEP 9, 2026 · JOURNAL ARTICLE

Sintilimab‑related cystitis/ureteritis in high‑grade endometrial stromal sarcoma: A case report and structured literature review

Human Vaccines & Immunotherapeutics

A single case report with literature review describing a rare adverse event; provides clinical observation and management guidance but lacks comparative data or controlled evidence of incidence or causality.

SEP 8, 2026 · JOURNAL ARTICLE

Endometrial Cancer: Epidemiological Aspects, Management, and Prognosis at the Department of Obstetrics and Gynecology, Donka National Hospital

International Journal of Clinical Oncology and Cancer Research

A single-centre retrospective descriptive study over 15 years with no comparator, control group, or analytical design; reports incidence and outcomes but cannot test causation or establish clinical efficacy.

SEP 7, 2026 · JOURNAL ARTICLE

The evolving role of open abdominal surgery in gynecological malignancies in the era of minimally invasive and precision oncology

World Journal of Surgical Oncology

A narrative review synthesizing current literature on surgical approaches in gynecological malignancies, offering expert consensus on the continuing role of open surgery alongside modern alternatives rather than reporting new empirical data.

SEP 7, 2026 · REVIEW

Artificial intelligence in endometrial cancer: multimodal deep learning and future perspectives in precision gynecologic oncology — a structured narrative review

Frontiers in Oncology

This is a narrative review synthesizing existing literature on AI applications in endometrial cancer; it does not report original empirical results, primary endpoints, or comparative efficacy data from controlled studies, and explicitly acknowledges that prospective clinical evidence remains insufficient.

SEP 5, 2026 · JOURNAL ARTICLE

Proteogenomic profiling defines progression-associated biology in high-risk endometrial cancer

npj Precision Oncology

A well-designed retrospective proteogenomic study with independent validation cohort showing that proteomic profiling improves risk stratification beyond clinical-genomic classifiers in high-risk endometrial cancer, but limited by single-center design, archival tissue, and lack of prospective validation or intervention outcome data.

SEP 2, 2026 · JOURNAL ARTICLE

Prevalence and Risk Factors of Endometrial Carcinoma Associated with Endometrial Polyps: A Retrospective Study of 2588 Polish Patients

Diagnostics

A large retrospective cohort confirming the low but clinically important prevalence of endometrial carcinoma in endometrial polyps (0.62%) and identifying established demographic and metabolic risk factors, with clear statistical analysis but observational design and no intervention.

AUG 18, 2026 · JOURNAL ARTICLE

Serplulimab combined with bevacizumab and chemotherapy as first-line treatment for recurrent or metastatic cervical cancer (ASTRUM-CC01): a phase II trial

Frontiers in Immunology

Single-arm phase II trial showing encouraging ORR and PFS in a small cohort, but lacks a control arm and mature OS data; results warrant phase III confirmation but do not yet change practice.